
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health is currently facing some short-term challenges with lower than expected results and a lowered outlook for FY26, but their strong partnership with Novo is expected to drive future growth. With a raised price target of $35 and a Buy rating, the company has potential for a $1 billion revenue and increased market opportunity. However, they must carefully navigate competition and maintain a favorable LTV to CAC ratio in the telehealth market while also addressing potential risks from regulations and changes in their business model. The recent collaboration with Novo to offer FDA approved medications should help mitigate previous legal concerns and support the company's overall growth.
Bears say
Hims & Hers Health is facing multiple challenges including slow revenue growth, declining margins, and increased regulatory scrutiny. Compounding pharmacies, which are key to Hims & Hers' business model, face potential tighter regulations that could impact the company's ability to offer customized medications. In addition, higher costs associated with shifting to branded drugs and potential data breaches could hurt Hims & Hers' profitability and reputation, while increasing volatility in the stock price. These challenges outweigh potential growth opportunities in the weight loss market and international expansion, leading to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares